We are grateful for having the opportunity to reply to the letter from Stephen McKenna and John Brodersen [1] , in which the authors discuss several issues related to our work. Our study was intended to pursue the work begun by others to provide normative data on the quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA) questionnaire to help interpret QoL-AGHDA data collected in growth hormone deficient (GHD) patients. In this context, we aimed to complete previous studies that enabled reference values for the QoL-AGHDA questionnaire to be collected in general populations in European countries [2] [3] [4] [5] [6] . Therefore, we would like to provide some clarification as it seems that the objective of our work has not been fully understood by the authors of the letter to editor.
The QoL-AGHDA questionnaire was developed according to the needs-based approach of QoL, and is indeed intended to be used in GHD patients and not in healthy individuals. Thus, the questionnaire was psychometrically validated in GHD patients in the UK, Sweden, Germany, Italy, and Spain [7] . The translation and psychometric validation of the French version of the QoL-AGHDA questionnaire in GHD patients was undertaken and published by Leplège et al. [8] in 2003. In 2000, Wiren et al. [6] published a work aiming to validate the QoL-AGHDA questionnaire in Sweden using Rasch analysis and to compare the QoL of GHD patients to that of a random sample of the Swedish population [6] . Reference values were collected in other European countries [2] [3] [4] [5] , but without measuring the scaling properties of the QoL-AGHDA questionnaire in general populations. The main purpose of our study was to collect reference QoL-AGHDA data for the French general population. To ensure scientifically sound results to be produced, we also assessed the psychometric properties of the French QoL-AGHDA questionnaire in our study sample.
Contrary to the study conducted by Wiren et al. [6] , our study was not designed to directly compare a patient sample to a random sample of the general population using Rasch analysis. In order to focus our article on the main objective (that was to provide additional reference values for the QoL-AGHDA questionnaire), we deliberately did not develop on technical aspects of the Rasch analysis in the article. Nevertheless, in order to clarify some doubts from the authors of the letter, we would like to state that the overall fit of our Rasch model was good (item-trait interaction p [ 2 ] ϭ 1000; separation index ϭ 0.88). We appreciate that it would have been interesting to explore the issue of differential item functioning (DIF) between males and females as regards the results observed on the mean QoL-AGHDA total score. The objective of the study, however, was to establish reference values on the observed score to make easy comparison with GHD patients. Correcting the score by gender for DIF would have prevented this simple and direct comparison, which, for example, may be conducted by clinicians to compare with QoL of their patients.
One major concern when using QoL instruments is the interpretation of data collected with such measures, and reference values represent a simple and direct way for clinicians to convert a QoL score given by a patient into interpretable and worthwhile information. Such reference data have been collected for many years, for both generic and specific questionnaires, including the QoL-AGHDA questionnaire [9 -12] . In particular, Wiren [6] compared QoL-AGHDA data between GHD patients and a random sample of the Swedish population, with no reference to the potential irrelevance of using such a population as comparator. We are thus surprised by the statement made by the authors of the letter about the irrelevance of comparison with healthy individuals, as Stephen Mc Kenna contributed to the Swedish study.
As explained in the article, the issue of which population should be used to compare QoL-AGHDA data in GHD patients remains an open question. Both general and other disease populations present advantages and disadvantages, and it seems obvious that the comparator should be chosen depending on the research question to be addressed [13, 14] . In the context of choosing the appropriate comparator, it is important to collect as much information as possible to enable a comparison that is as accurate and relevant as possible to be conducted. Our study falls within this framework as we chose to collect reference values in the French general population to complete previous studies. Moreover, reference values collected in general populations have a major additional interest compared to reference values collected in disease populations: they may enable utility values to be derived for use in economic evaluation [15] . 
